Clinical and therapeutic characterization of patients diagnosed with medication-related osteonecrosis of the jaws
Keywords:
Medication-related osteonecrosis of the jaws, bisphosphonates, ozone therapy, laser therapy.Abstract
Introduction: Medication-related osteonecrosis of the jaws is an affection associated with the treatment with bisphosphonates, antiresorptive agents or antiangiogenic medications.
Objective: To perform a clinical and therapeutic characterization of patients with the diagnosis of medication-related osteonecrosis of the jaws.
Material and Method: A case series of a total of 19 patients with the diagnosis of medication-related osteonecrosis of the jaws was carried out in the Department of Dental and Maxillofacial Surgery of ¨Raúl González Sánchez¨ Dental School of Havana from January 2018 to January 2019. The severity and risk factors were identified and the treatment including the healing with ozone oil and the application of infrared laser was standardized. The patients were evaluated in the 90 days after treatment. The operationalization of variables included: sex, type of medications, ways and time of administration, localization, and evaluation of treatment.
Results: The average age of patients was 69±8,5 years and 52,63% of them were male. Zolendronate was the most associated agent in 78,95% of cases. Periodontal disease was the most identified local factor (57, 89%). The posterolateral area of the mandible and stage 2 disease evolution predominated in 63,16% and 52, 63% of lesions, respectively. Also 78, 94% of cases had a satisfactory evolution in the 90 days after treatment.
Conclusions: The administration of intravenous bisphosphonates, particularly Zolendronate, was the main cause of osteonecrosis. These lesions were mainly located in the posterior lateral area of the mandible and presented stage 2 disease evolution. Healing with ozone oil and application of infrared laser was the most implemented alternative treatment. The values of resolved and improved lesions were satisfactory in the 90 days after treatment.Downloads
References
1. Fernández E, Padilla P. Osteonecrosis mandibular relacionada con medicamentos: conceptos teóricos y prácticos actuales para el odontólogo general. Odontología Vital [Internet].2018 Dic [Citado 28/02/2020];29:19-32. Disponible en: https://www.scienceopen.com/document?vid=c69dc00f-8980-44e4-acfb-c45288d5109b
2. Ruggiero SL, Dodson TB. American Association of Oral and Maxillofacial Surgeons American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg [Internet]. 2014 Jul [Citado 22/02/2020];72:1938-56. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/25234529
3. Díaz Reverand S, Navas Gíaz L. Manejo de la osteonecrosis maxilar asociada al uso de medicamentos en virtud de su estadio clínico: análisis de 19 casos. Rev Esp Cir Oral Maxilofac [Internet]. 2018 Jul [Citado 22/02/2020];40(3):104-11. Disponible en: https://doi.org/10.1016/j.maxilo.2017.06.001
4. Holtmann H, Lommen J. Pathogenesis of medication-related osteonecrosis of the jaw: a comparative study of in vivo and in vitro trials. J Int Med Res [Internet].2018 Oct [Citado 20/02/2020];46(10):4277-96. Disponible en: https://dx.doi.org/10.1177%2F0300060518788987
5. Manfredi M, Mergoni G. A 5-year retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zoledronic acid for bone metastases from solid tumors. Med Oral Patol Oral Cir Bucal [Internet].2017 May [Citado 21/02/2020];22(3):ee42-8. Disponible en: https://dx.doi.org/10.4317%2Fmedoral.21728
6. Weitzman R, Sauter N. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients—May. Crit Rev Oncol Hematol [Internet]. 2007 May [Citado 21/02/2020];62(2):148-52. Disponible en: https://doi.org/10.1016/j.critrevonc.2006.12.005
7. Schiodt M, Vadhan Raj S. A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer. Support Care Cancer [Internet].2018 Dic [Citado 21/02/2020];26(6):1905-15. Disponible en: https://dx.doi.org/10.1007%2Fs00520-017-4003-2
8. Saia G, Blandamuera. Occurrence of Bisphosphonate related osteonecrosis of the jaw after surgical tooth extraction. J Oral Maxillofac Surg [Internet]. 2010 Abr [Citado 20/02/2020];68(4):797-804. Disponible en: https://doi.org/10.1016/j.joms.2009.10.026
9. Bermúdez Bejerano EB. Bermúdez Bejerano M. ¿Es la enfermedad periodontal un factor de riesgo de quimio-osteonecrosis maxilar asociada a bisfosfonatos?. Actual Med [Internet]. 2017 Sept [Citado 20/02/2020];102:(802):162-8. Disponible en: https://doi.org.10.15568/am.2017.802.re01
10. Thumbigere Math V, Michalowicz BS. Periodontal disease as a risk factor for bisphosphonate-related osteonecrosis of the jaw. J Periodontol [Internet]. 2014 Feb [Citado 20/02/2020];85(2):226-33. Disponible en: https://doi.org/10.1902/jop.2013.130017
11. Giovannacci I, Meleti M. Medication-Related Osteonecrosis of the Jaw Around Dental Implants. J Craniofac Surg [Internet]. 2016 May [Citado 20/02/2020];27:697-701. Disponible en: https://doi.org/10.1097/SCS.0000000000002564
12. Granate M A, Polis Yanes C. Medication-related osteonecrosis of the jaw associated with implant and regenerative treatments: Systematic review. Med Oral Patol Oral Cir Bucal [Internet]. 2019 Mar [Citado 23/02/2020];24(2):e195-e203. Disponible en https://dx.doi.org/10.4317%2Fmedoral.22691
13. Fliefel R, Trölzsch M. Treatments strategies and outcomes of bisphosphonate related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. Int J Oral Maxillofac Surg [Internet]. 2015 May [Citado 23/02/2020];44:568-85. Disponible en: https://doi.org/10.1016/j.ijom.2015.01.026
14. Beth Tasdogan NH, Mayer B. Interventions for managing medication-related osteonecrosis of the jaw (MRONJ). Cochrane Database of Systematic Reviews Protocol [Internet]. 2017 Oct [Citado 23/02/2020];10(10):CD012432. Disponible en: https://dx.doi.org/10.1002%2F14651858.CD012432.pub2
Download PDF
